In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jessica Merrill

New York, NY
Jessica Merrill is a Senior Editor for US Commercial Content for Informa’s pharmaceutical news publications, including “The Pink Sheet” and SCRIP. She has been covering the pharmaceutical industry as a journalist for more than 10 years, spanning the spectrum from R&D to regulatory to commercial. She was previously a reporter and editor for “The Pink Sheet” and “Pink Sheet” DAILY, specializing in business and commercial news, focusing largely on big pharma, M&A and business development, and the commercial landscape, including drug launches and market access. Before embarking on a career in healthcare journalism, she covered business news for the cosmetics industry and worked as a newspaper reporter.

Latest From Jessica Merrill

Rocket Fires Up CV Gene Therapy Pipeline With Renovacor Merger

Rocket's all-stock acquisition of Renovacor is valued at about $53m and adds a preclinical portfolio targeting genetically driven cardiovascular disease.

Deals Gene Therapy

Virios Fibromyalgia Drug Fails Phase IIb And Firm Says COVID-19 May Be To Blame

A Phase IIb trial testing IMC-1 for fibromyalgia failed to reach statistical significance on the primary pain endpoint, but one cohort showed an improvement and Virios intends to pursue the drug further.

Clinical Trials Business Strategies

Terlivaz Approved By FDA As Mallinckrodt Seeks To Advance New Business Strategy

Terlivaz is the first product approved to improve kidney function in adults with hepatorenal syndrome (HRS). The approval is a milestone in a long regulatory road for the drug.

Approvals Rare Diseases

Capstan Launches, Backed By Big Names And Big Pharma, To Pioneer In Vivo Cell Therapies

The start-up, founded on science from the University of Pennsylvania, announced a $102m series A financing and the appointment of former Silverback CEO Laura Shawver as CEO.

StartUps and SMEs Research & Development

ICER Pushes ALS Drug Makers To Moderate Launch Price While Awaiting Confirmatory Data

The US drug pricing watch dog issued a final assessment on Amylyx's AMX0035 and Mitsubishi Tanabe's Radicava for ALS.

Pricing Debate Neurology

Regeneron Gets Encouraging Early Data For Bispecifics In Solid Tumors

The company presented positive early data at ESMO for two bispecific antibodies that are important to the company's long-term business strategy, MUC16xCD3 and METxMET.

Clinical Trials ImmunoOncology
See All
UsernamePublicRestriction

Register